Ligand-tethered Lipid Nanoparticles for Targeted RNA Delivery to Treat Liver Fibrosis
the Mitchell Lab has developed a new class of anisimide-functionalized lipids that enables targeted delivery of lipid nanoparticles (LNPs) to activated fibroblasts in the liver.
Penn Ranks First in Licensing Income
Penn officially ranked number one in terms of licensing income in the latest Association of University Technology Managers (AUTM) annual survey, which included 153 reporting institutions.
PCI Activities Highlighted by the CEO Council for Growth
The CEO Council for Growth recently highlighted PCI's annual review and JP Morgan Conference event in its newsletter.
PACT Enterprise Awards
PCI supported Penn spinouts Interius BioTherapeutics, Verismo Therapeutics, viTToria biotherapeutics, Exyn Technologies, and Avisi Technologies are all nominated for awards.
Mitchell Lab’s Targeted Prenatal Therapy for Mothers and Their Babies Addresses Gap in Health Equity
The researchers’ successful trials in mice show that the technology may potentially lead to promising treatment options for humans with pre-eclampsia.
Penn Medicine, CHOP receive $25M anonymous gift to accelerate research in rare genetic brain disorders
The donation will establish the Center for Epilepsy and Neurodevelopmental Disorders, which will initially focus on developing therapies for disorders related to genetic mutations that are linked to a
Eidos LGBTQ+ Health Initiative Support Advances in LGBTQIA+ Health Startups
The goal of the partnership is to support founders and entrepreneurs with in-depth LGBTQ+ health knowledge and research expertise.
Equimeter Wins $10,000 2023 Penn Y-Prize
The Equimeter team consisted of undergraduates Ujjayi Pamidigantam (Vagelos LSM), Parthiv Patel (Vagelos LSM), and Advait T. (Vagelos LSM)
Nia Therapeutics and Peroxitech Raise Venture Funding
Two Penn spinout companies have recently brought in major investments to help further advance their technologies.